Reduced stratifin expression can serve as an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma

Digestive Diseases and Sciences

Volumn 55, Issue 9, 2010, Pages 2552-2560

  Ren, Hong Zheng ^a   Pan, Guo Qing ^a   Wang, Jin Sheng ^b   Wen, Ji Fang ^a   Wang, Kuan Song ^a   Luo, Geng Qiu ^a   Shan, Xu Zheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CHANGZHI MEDICAL COLLEGE   (China)

Author keywords

Esophageal squamous cell carcinoma; Prognostic indicator; Stratifin

Indexed keywords

MESSENGER RNA; STRATIFIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; WESTERN BLOTTING;

14-3-3 PROTEINS; ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; EXONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77956190341     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1065-0     Document Type: Article

References (27)

1. GD Stoner A Gupta 2001 Etiology and chemoprevention of esophageal squamous cell carcinoma Carcinogenesis 22 11 1737 1746 10.1093/carcin/22.11.1737 10.1093/carcin/22.11.1737 11698334 (Pubitemid 33064837)
2. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 2 74 108 10.3322/canjclin.55.2.74 10.3322/canjclin.55.2.74 15761078
3. W Wang DC Shakes 1996 Molecular evolution of the 14-3-3 protein family J Mol Evol 43 4 384 398 10.1007/BF02339012 10.1007/BF02339012 8798343
4. M Rosenquist P Sehnke RJ Ferl M Sommarin C Larsson 2000 Evolution of the 14-3-3 protein family: does the large number of isoforms in multicellular organisms reflect functional specificity? J Mol Evol 51 5 446 458 11080367
5. MK Dougherty DK Morrison 2004 Unlocking the code of 14-3-3 J Cell Sci 117 Pt10 1875 1884 10.1242/jcs.01171 10.1242/jcs.01171 15090593 (Pubitemid 38745122)
6. H Fu RR Subramanian SC Masters 2000 14-3-3 proteins: structure, function, and regulation Annu Rev Pharmacol Toxicol 40 617 647 10.1146/annurev.pharmtox. 40.1.617 10.1146/annurev.pharmtox.40.1.617 10836149 (Pubitemid 30340695)
7. C MacKintosh 2004 Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes Biochem J 381 Pt2 329 342 10.1042/BJ20031332 15167810 (Pubitemid 38976512)
8. P Mhawech 2005 14-3-3 proteins-an update Cell Res 15 4 228 236 10.1038/sj.cr.7290291 10.1038/sj.cr.7290291 15857577 (Pubitemid 41642878)
9. S Dhar JA Squire MP Hande RJ Wellinger TK Pandita 2000 Inactivation of 14-3-3sigma influences telomere behavior and ionizing radiation induced chromosomal instability Mol Cell Biol 20 20 7764 7772 10.1128/MCB.20.20.7764- 7772.2000 10.1128/MCB.20.20.7764-7772.2000 11003671
10. KJ Livak TD Schmittgen 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method Methods 25 4 402 408 10.1006/meth.2001.1262 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
11. A Perathoner D Pirkebner G Brandacher, et al. 2005 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients Clin Cancer Res 11 9 3274 3279 10.1158/1078-0432.CCR-04-2207 10.1158/1078-0432.CCR-04-2207 15867223 (Pubitemid 40627875)
12. G Gastl G Spizzo P Obrist M Dünser G Mikuz 2000 Ep-CAM overexpression in breast cancer as a predictor of survival Lancet 356 9246 1981 1982 10.1016/S0140-6736(00)03312-2 10.1016/S0140-6736(00)03312-2 11130529
13. S Yan C Zhou W Zhang, et al. 2008 β-catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma Cancer Lett 271 1 85 97 10.1016/j.canlet.2008.05.035 10.1016/j.canlet.2008.05.035 18602747
14. FL Greene DL Page ID Fleming, et al. 2002 AJCC Cancer Staging Manual 6 Springer-Verlag New York 10.1007/b97251
15. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002. doi: 10.1007/b97251.
16. N Iwata H Yamamoto S Sasaki, et al. 2000 Frequent hypermethylation of CpG islands and loss of expression of the gene in human hepatocellular carcinoma Oncogene 19 46 5298 5302 10.1038/sj.onc.1203898 10.1038/sj.onc.1203898 11077447
17. E Dellambra O Golisano S Bondanza, et al. 2000 Downregulation of 14-3-3 prevents clonal evolution and leads to immortalization of primary human keratinocytes J Cell Biol 149 5 1117 1130 10.1083/jcb.149.5.1117 10.1083/jcb.149.5.1117 10831615 (Pubitemid 30354261)
18. CB Umbricht E Evron E Gabrielson A Ferguson J Marks S Sukumar 2001 Hypermethylation of 14-3-3sigma (stratifin) is an early event in breast cancer Oncogene 20 26 3348 3353 10.1038/sj.onc.1204438 10.1038/sj.onc.1204438 11423985 (Pubitemid 32588983)
19. J Akahira Y Sugihashi T Suzuki, et al. 2004 Decreased expression of 14-3-3sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation Clin Cancer Res 10 8 2687 2693 10.1158/1078-0432.CCR-03-0510 10.1158/1078-0432.CCR-03-0510 15102672 (Pubitemid 38509143)
20. H Suzuki F Itoh M Toyota T Kikuchi H Kakiuchi K Imai 2000 Inactivation of the 14-3-3σ gene is associated with 5 V CpG island hypermethylation in human cancers Cancer Res 60 16 4353 4357 10969776
21. H Osada Y Tatematsu Y Yatabe, et al. 2002 Frequent and histologic type-specific inactivation of 14-3-3σ in human lung cancers Oncogene 21 15 2418 2424 10.1038/sj.onc.1205303 10.1038/sj.onc.1205303 11948426
22. CD Logsdon DM Simeone C Binkley, et al. 2003 Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer Cancer Res 63 10 2649 2657 12750293
23. Y Ito E Miyoshi E Uda, et al. 2003 14-3-3sigma possibly plays a constitutive role in papillary carcinoma, but not in follicular tumor of the thyroid Cancer Lett 200 2 161 166 10.1016/S0304-3835(03)00282-9 10.1016/S0304-3835(03)00282-9 14568170 (Pubitemid 38366097)
24. JM Moreira P Gromov JE Celis 2004 Expression of the tumor suppressor protein 14-3-3sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition Mol Cell Proteomics 3 4 410 419 10.1074/mcp.M300134-MCP200 10.1074/mcp.M300134-MCP200 14736829 (Pubitemid 38713923)
25. H Okumura S Natsugoe M Matsumoto, et al. 2005 Predictive value of p53 and 14-3-3sigma for the effect of chemoradiationtherapy on esophageal squamous cell carcinoma J Surg Oncol 91 1 84 89 10.1002/jso.20279 10.1002/jso.20279 15999354 (Pubitemid 40967386)
26. Y Kuroda S Aishima A Taketomi, et al. 2007 14-3-3σ negatively regulates the cell cycle, and its down-regulation is associated with poor outcome in intrahepatic cholangiocarcinoma Hum Pathol 38 7 1014 1022 10.1016/j.humpath.2006.12.014 10.1016/j.humpath.2006.12.014 17391729 (Pubitemid 46899146)
27. L Cheng CX Pan JT Zhang, et al. 2004 Loss of 14-3-3sigma in prostate cancer and its precursors Clin Cancer Res 10 9 3064 3068 10.1158/1078-0432.CCR- 03-0652 10.1158/1078-0432.CCR-03-0652 15131044 (Pubitemid 38619684)